We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Congenital Cytomegalovirus Infection Predicted in High-Risk Pregnant Women

By LabMedica International staff writers
Posted on 08 Dec 2016
Congenital cytomegalovirus (CMV) infection can cause serious complications such as hearing difficulties and mental delay in affected infants. A new method for predicting congenital CMV infection during the prenatal period has been discovered. This method is safe for both mothers and fetuses, and could potentially be adopted for general use.

In the USA over 8,000 children a year suffer from the long-term complications of congenital CMV infection and the annual costs of caring for these children are estimated at USD 1-2 billions. To facilitate this, early diagnosis is vital; however, tests to identify the infection in infants, such as molecular tests that detect virus DNA in infants' urine, are not widely carried out, and would incur huge financial costs if they were carried out for all infants.

Image: Transmission electron microscopic (TEM) depicts numbers of cytomegalovirus (CMV) virions that were present in a tissue sample (Photo courtesy of Sylvia Whitfield).
Image: Transmission electron microscopic (TEM) depicts numbers of cytomegalovirus (CMV) virions that were present in a tissue sample (Photo courtesy of Sylvia Whitfield).

Scientists affiliated with the Kobe University Graduate School of Medicine (Kobe, Japan) surveyed 300 pregnant women who tested positive for CMV immunoglobulin M (IgM) antibodies and were classified as high-risk for congenital infection. The team carried out clinical interviews, blood tests, ultrasounds, and DNA polymerase chain reaction (PCR) tests for CMV using samples of the subjects' blood, urine and uterine cervical secretion. The maternal clinical and laboratory findings, including serum CMV IgM and IgG, IgG avidity index (AI), direct immunoperoxidase staining of leukocytes with peroxidase-labeled monoclonal antibody (C7-HRP test) testing, and PCR for the detection of CMV-DNA in the maternal serum, urine, and uterine cervical secretion, and prenatal ultrasound findings were evaluated.

The team reported that in 22 of the 300 women, congenital infection was confirmed using PCR for CMV-DNA in newborn urine. Univariate analyses demonstrated that the presence of maternal flu-like symptoms, presence of ultrasound fetal abnormalities, serum titers of CMV IgM, positive results for C7-HRP, CMV IgG AI less than 40%, and positive PCR results in the uterine cervical secretion were statistically associated with the occurrence of congenital CMV infection. Multivariable analysis revealed that the presence of ultrasound fetal abnormalities and positive PCR results in the uterine cervical secretion were independent predictive factors of congenital CMV infection in CMV IgM-positive women.

The authors concluded that both ultrasound and PCR tests for uterine cervical secretion are non-invasive procedures, and using them can offer a safer method to test high-risk pregnant women and predict the occurrence of congenital infection. Accurately identifying the affected infants enables doctors to start antiviral treatment early, and could improve the neurological prognosis of infants infected by CMV. The study was published online on October, 20, 2016, in the journal Clinical Infectious Diseases.

Related Links:
Kobe University Graduate School of Medicine


Gold Member
Hematology Analyzer
Swelab Lumi
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Chemistry Analyzer
MS100
New
Auto-Chemistry Analyzer
CS-1200

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients